X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024
X4 Pharmaceuticals (Nasdaq: XFOR) has announced it will report its third-quarter 2024 financial results and present findings from its completed Phase 2 clinical trial of mavorixafor in chronic neutropenia patients on November 13, 2024. The company will host a conference call and webcast at 8:00 a.m. ET on the same day. The presentation will be accessible via phone and through the company's investor relations website, with a replay available afterward.
X4 Pharmaceuticals (Nasdaq: XFOR) ha annunciato che riporterà i suoi risultati finanziari del terzo trimestre 2024 e presenterà i risultati del suo completato studio clinico di Fase 2 su mavorixafor nei pazienti con neutropenia cronica il 13 novembre 2024. L'azienda ospiterà una conferenza telefonica e un webcast alle 8:00 ET dello stesso giorno. La presentazione sarà accessibile tramite telefono e tramite il sito web delle relazioni con gli investitori dell'azienda, con una registrazione disponibile in seguito.
X4 Pharmaceuticals (Nasdaq: XFOR) ha anunciado que informará sobre sus resultados financieros del tercer trimestre de 2024 y presentará hallazgos de su prueba clínica de fase 2 completada de mavorixafor en pacientes con neutropenia crónica el 13 de noviembre de 2024. La compañía llevará a cabo una conferencia telefónica y un webcast a las 8:00 a.m. ET el mismo día. La presentación será accesible por teléfono y a través del sitio web de relaciones con inversores de la empresa, con una repetición disponible posteriormente.
X4 제약 (Nasdaq: XFOR)는 2024년 3분기 재무 결과를 보고하고 만성 중성구역환자에서 mavorixafor의 완료된 2상 임상 시험 결과를 발표할 것이라고 발표했습니다. 발표는 2024년 11월 13일에 진행됩니다. 회사는 같은 날 오전 8시 ET에 전화 회의 및 웹캐스트를 주최할 예정입니다. 발표는 전화로 또는 회사의 투자자 관계 웹사이트를 통해 접근 가능하며, 이후 재생이 가능합니다.
X4 Pharmaceuticals (Nasdaq: XFOR) a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 et présentera les résultats de son essai clinique de phase 2 complété sur le mavorixafor chez des patients atteints de neutropénie chronique le 13 novembre 2024. L'entreprise organisera une conférence téléphonique et un webinaire à 8h00, heure de l'Est, le même jour. La présentation sera accessible par téléphone et via le site web des relations investisseurs de la société, avec une rediffusion disponible par la suite.
X4 Pharmaceuticals (Nasdaq: XFOR) hat angekündigt, dass es seine Finanzergebnisse für das dritte Quartal 2024 veröffentlichen und Ergebnisse aus seiner abgeschlossenen Phase-2-Studie zu mavorixafor bei Patienten mit chronischer Neutropenie am 13. November 2024 präsentieren wird. Das Unternehmen wird am selben Tag um 8:00 Uhr Eastern Time eine Telefonkonferenz und ein Webcast veranstalten. Die Präsentation ist telefonisch und über die Website für Investorenbeziehungen des Unternehmens zugänglich, mit einer Wiederholung, die anschließend verfügbar ist.
- None.
- None.
BOSTON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the third quarter ended September 30, 2024 and present results from its concluded Phase 2 clinical trial evaluating mavorixafor in people with chronic neutropenia on Wednesday, November 13, 2024.
The company will host a conference call and webcast on the same day at 8:00 a.m. ET. The conference call can be accessed by dialing 1-800-267-6316 from the United States or 1-203-518-9783 internationally, followed by the conference ID: X4PHARMA. The live webcast and accompanying slide presentation will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the conclusion of the call and webcast, a replay will be available on the company’s website.
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI® (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
When will X4 Pharmaceuticals (XFOR) report its Q3 2024 financial results?
What clinical trial results will X4 Pharmaceuticals (XFOR) present on November 13, 2024?
How can investors access X4 Pharmaceuticals' (XFOR) Q3 2024 earnings call?
